The FACTOR-64 study was a randomized clinical trial in which 900 patients with type 1 or type 2 diabetes of at least 3 to 5 years ' duration and without symptoms of CAD were recruited from 45 clinics and practices of a single health system ( Intermountain Healthcare , Utah ) , enrolled at a single-site coordinating center , and randomly assigned to CAD screening with CCTA ( n = 452 ) or to standard national guidelines-based optimal diabetes care ( n = 448 ) ( targets : glycated hemoglobin level < 7.0 % , low-density lipoprotein cholesterol level < 100 mg/dL , systolic blood pressure < 130 mm Hg ) .